Basic Publications The Committee did not identify any quality quality literature that reported cannabis or cannabinoids as an effective treatment for AIDS wasting syndrome that was published after the recent well-researched or relevant systematic review data. research question.
This is largely due
- To the apparent disappearance
- Of the syndrome
- Since effective antiretroviral
- Drugs became available
- In the mid-1990’s
Systematic Review The committee did not identify any quality or appropriate quality reviews that reported cannabis or cannabinoids as an effective treatment for cancer-related anorexia-cachexia syndrome.
Primary Literature A Phase III multicenter, randomized, double-blind-blind-placebo-controlled trial was conducted by the Cannabis-In-Cachexia-Study-Group in patients with cancer-related anorexia-cachexia syndrome (Strasser et al., 2006).
Patients with advanced
Cancer and weight loss of more than 5 percent at 6 months were randomly assigned to 2: 2: 1 Cannabis gummies for detoxification (limited to THC 2.5 mg and cannabidiol 1.0 mg), THC 2.5 mg, or i -placebo twice a day. 6 weeks. Diet, emotions, and nausea were observed daily.
Cancer-related health status and cannabinoid-related toxicity were also noted. Only 164 of the 243 patients completed the study. Therapeutic purpose analysis did not reveal differences between groups of satisfaction, quality of life, or toxicity.
An increase in appetite
Was reported with 73 percent cannabis-extract, 58 percent of the THC group, and 69 percent of placebo recipients. The recruitment was completed early by the data review board because it is believed that there is little chance of a difference in treatment weapons.
The findings of this study reinforce the results from a previous study investigating dronabinol, megestrol acetate, or a combination of 469 advanced cancer patients with loss of appetite and weight loss of Cannabis edible than 5 pounds over the past 2 months (Jatoi et al., 2002). ).
Megestrol acetate
Was higher than dronabinol to improve both appetite and weight, with combination therapy providing no additional benefit. Seventy-five percent of megestrol recipients reported an improvement in appetite compared to 49 percent of those receiving dronabinol (p = 0.0001). Of those in the compound arm, 66 percent reported improvement.
Weight gain or greater than 10 percent above their baseline over time during the trial reported 11 percent of those on Weed gummies, compared to 3 percent of dronabinol recipients (p = 0.02). The combined arm reported an 8 percent weight gain. These findings confirm similarly performed studies performed on patients with AIDS wasting syndrome (Timpone et al., 1997).
Anorexia Nervosa
Systematic Review The committee did not identify a systematic review of quality or appropriate reporting of medical marijuana as an effective treatment for anorexia nervosa.
Primary Literature Pharmacological interventions in the treatment of anorexia nervosa have not been promising until now. Andries et al. (2014) conducted a prospective, randomized, double-blind, controlled crossover trial of 24 women with anorexia nervosa for at least 5 years attending both psychiatric and somatic treatment as inpatients or outpatients.
In addition to their
Regular psychotherapy and nutrition interventions, participants received dronabinol 2.5 mg twice daily for 4 weeks and a corresponding placebo for 4 weeks, randomly given two doses of treatment (dronabinol / placebo or i). -placebo / dronabinol). The main result was a weight change that was checked weekly. The second result was a change in Eating Disorder Inventory-2 (EDI-2) scores.
Participants had
A significant weight of 1.00 kg (95% CI = 0.40-1.62) during dronabinol treatment and 0.34 kg (95% CI = 00.14-0.82) during placebo (p = 0.03). No statistically significant difference in EDI-2 score variables was observed during treatment with Thc gummies or placebo, suggesting that there was no real effect on participants’ psychological and behavioral factors related to eating disorders.
The authors conceded a small sample size and short exposure time, as well as potential psychogenic effects, but concluded that low-dose dronabinol is a safe adjuvant palliative treatment for a small select group of chronically malnourished women with anorexia nervosa.
